ClinicalTrials.gov
public full text
Public Domain
Celecoxib Treatment for Lung Cancer
This proposal evaluates cyclooxygenase 2 (COX-2) inhibition as a means to decrease T regulatory cell activities and thus augment immune responses against lung cancer. The broad goal focuses on understanding how COX-2 expression regulates the malignant phenotype in non small cell lung cancer in an effort to foster an informed approach for the use of COX-2 inhibitors in prevention and therapy for lung cancer.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Window of Opportunity Trial of Durvalumab (MEDI4736) to Identify Immune Dynamics in Operable Non-small Cell Lung Cancer (NSCLC) (MIRACLE)#877962
- Use of Cetuximab for Unresectable or Metastatic Esophageal and Gastric Cancer#917666
- The Effect of a Non-hormonal Cox-2 Inhibitor (Celebrex) on Ovulation#902816
- Tecemotide Following Concurrent Chemo-radiotherapy for Non-small Cell Lung Cancer#870933
- Phase II Study of Celecoxib and Concurrent Radiotherapy in Stage II-III NSCLC#1031133
Record · ID 884139
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive